PL-6983 is the lead compound in a new series of melanocortin receptor-specific peptides developed by Palatin Tech, NJ USA.* PL-6983 has demonstrated effective safe results in inducing erections in animal model study and in inducing sexual behavior in a model for female sexual dysfunction (FSD) clinical research.
PalatinTechnologies is developing PL6983 primarily for FSD, a major medical need dependent on results of ongoing clinical trials, Biotech companies may also seek to develop PL-6983 for erectile dysfunction (ED).
Reply With Quote